timothy sykes logo
CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals Thumbnail
ADD US ONG Google News

CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals

TIM SYKES•UPDATED MAR. 21, 2026, 10:04 AM ET
Reviewed by Bryce Tuohey Fact-checked by Matt Monaco

Vanda Pharmaceuticals Inc.’s stocks have been trading down by -17.63 percent amid strategic uncertainty and market repositioning concerns.

Candlestick Chart

Weekly Update Mar 16 – Mar 20, 2026: On Saturday, March 21, 2026 Vanda Pharmaceuticals Inc. stock [NASDAQ: VNDA] is trending down by -17.63%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

  1. Market Position & Fundamentals: Vanda Pharmaceuticals (VNDA) is in a challenging market position, indicated by its deteriorating profitability metrics. The company’s EBIT margin stands at -48.6%, and its profit margin is deeply negative at -88.37%. Revenue has declined over the past three and five-year periods by 5.29% and 2.73%, respectively. Although VNDA has a strong gross margin of 72.4%, the unsustainable expense structure, evident in the negative EBITDA margin of -45.7%, affects profitability. The current ratio at 2.4 suggests adequate short-term liquidity, but substantial negative net income from continuing operations, amounting to -$141.2 million, casts doubt on near-term financial stability. The high book value per share at $5.54, relative to its price-to-book ratio of 1.55, indicates undervaluation, but negative cash flow from operations implicates significant operational inefficiencies.

  2. Technical Analysis & Trading Strategy: Recent weekly candlestick patterns illustrate a dominant bearish trend dominating Vanda Pharmaceuticals’ stock price movement. Starting from $8.81 to a low of $7.0591, the stock has consistently formed lower highs and lower lows, reflecting downward momentum. The low volume around recent price levels suggests a lack of buying interest, confirming bearish sentiments. The actionable trading strategy would involve shorting the stock on rallies near resistance levels, such as the $9.57 mark seen earlier in the period, and targeting support near $7, contingent on reinforcement from volume spikes. Breaks below $7 with increased volume could signal new lows, and stop-loss orders should be placed judiciously above recent peaks.

  3. Catalysts & Outlook: VNDA faces pivotal challenges, including the outright sale of shares by CEO Mihael Polymeropoulos, reducing personal financial commitment, and regulatory setbacks in Europe. The CHMP’s recent rejection of VNDA’s antipsychotic iloperidone could significantly hinder European expansion prospects, a crucial growth market. Despite these adverse events, VNDA maintains $263.8 million in cash and cash equivalents, potentially sustaining operations and funding further strategic pivots or R&D recovery efforts. Compared to broader industry benchmarks, VNDA lags as these disruptions culminate in investor uncertainty. Immediate resistance rests at $9.5, while support is anticipated around $6.8. Overall, given the negative sentiment and substantial operational hurdles, sentiment remains cautiously negative despite liquidity buffers.

Quick Financial Overview

In the volatile realm of biotechnology, Vanda Pharmaceuticals faces a wave of challenges underscored by recent actions and unfolding circumstances. The decision by the European Medicines Agency to reject the marketing authorization of iloperidone echoes in financial metrics that have seen strain. The company grappled with a gross profit margin of 72.4%, yet recorded a stark net income loss of $141.2M as of the last quarter of 2025, highlighted by EBIT and EBITDA margins in negative territory. Investors eye the unusual sale of shares by the CEO, considering its proximity to the unfavorable regulatory feedback on iloperidone, which compounds existing investor hesitancies.

The company reported a significant revenue of $216.1M for the fiscal year; however, persistent challenges in maintaining profitability and returning positive shareholder equity bring focus to their tangible asset yields and operating cash flows meager at -$29.4M. Such figures underline expectations for strategic recalibration that could stir market movements. Highlights from recent intraday ventures reflect stock price actions down from a high of $9.6 to hovering near $7.06, thus revealing the market’s cautious stance amid these developments.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading VNDA

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”